West Pharmaceutical Services, Inc.
WSTHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, West Pharmaceutical Services, Inc. focuses on Medical Instruments & Supplies services and products. West Pharmaceutical Services, Inc. Valued at $27.60B, WST is a large-cap name in its sector. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Market Cap
$27.60B
Beta
1.13
P/E (TTM)
50.21
P/E (Fwd)
39.28
EPS (TTM)
$7.81
EPS (Fwd)
$9.98
ROE
19.1%
ROA
11.4%
Cash
$435.8M
Total Debt
$316.5M
Free CF
$277.9M
52W Change
36.5%
Annual Financials
Cash vs Debt
Where WST stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, WST finished 17.43% above its 150-day moving average ($326.94) and 24.81% above its 200-day moving average ($307.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WST overbought or oversold?
At the October 20, 2026 close, WST's RSI(14) was 56.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
West Pharmaceutical Services, Inc. holds $435.8M in cash against $316.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $277.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 19.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.4% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $2.89B (2022) to $3.07B (2025).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for West Pharmaceutical Services, Inc. and its sector.